IMMOBILIZED FATTY ACIDS FOR REVERSIBLE ALBUMIN BINDING

Information

  • Research Project
  • 2445244
  • ApplicationId
    2445244
  • Core Project Number
    R44HL050224
  • Full Project Number
    5R44HL050224-03
  • Serial Number
    50224
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/1994 - 30 years ago
  • Project End Date
    6/30/2001 - 23 years ago
  • Program Officer Name
  • Budget Start Date
    7/1/1997 - 27 years ago
  • Budget End Date
    6/30/2001 - 23 years ago
  • Fiscal Year
    1997
  • Support Year
    3
  • Suffix
  • Award Notice Date
    6/18/1997 - 27 years ago
Organizations

IMMOBILIZED FATTY ACIDS FOR REVERSIBLE ALBUMIN BINDING

Materials used in blood-contacting medical devices must be improved to reduce surface-induced thrombogenesis. The objective of this Phase II project is to immobilize fatty acid analogs onto biomaterials to enhance binding of endogenous albumin and, thereby, improve their blood compatibility. During Phase I, eight photoactivatible analogs of fatty acids were synthesized, immobilized on polyurethane, polyvinylchloride, and polyethylene, and tested in vitro for albumin binding and indicators of thrombogenicity. One reagent appeared particularly promising for enhancing albumin binding and reducing platelet attachment and activation. During Phase II, photoactivatible polyacrylamides with pendant fatty acids and heterobifunctional PEG derivatives containing fatty acids will be synthesized and immobilized onto polyethylene, silicone rubber, polyvinylchloride, and polyurethane. ESCA and TOF-SIMS will be used to ensure presence, completeness, and uniformity of the immobilized fatty acids. Surface-modified materials will be challenged with abrasion, sterilization, and washing to determine physical durability. Albumin and fibrinogen adsorption, anti-fibrinogen antibody binding, and platelet adhesion and activation will be tested in vitro. Acute, dog jugular vein implants will be conducted to screen surfaces for improvements m blood compatibility. Surfaces which perform well in the screening assays will be tested in 14- and 90-day sheep carotid artery implants and 5-month sheep mitral valve implants. PROPOSED COMMERCIAL APPLICATION: The development of materials with enhanced hemocompatibility is needed in the medical device market. The photoimmobilization technology for introducing fatty acids onto biomaterial surfaces proposed in this grant application would be readily applicable to nearly all polymers used currently in blood-contacting medical devices. Therefore, this surface modification strategy would have substantial impact in improving these devices and, consequently, would have significant commercial potential.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    SURMODICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    EDEN PRAIRIE
  • Organization State
    MN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    55344
  • Organization District
    UNITED STATES